Skip to main content
S&P 5007,610.34+0.32%DOW52,028.07-0.12%NASDAQ26,153.23+0.66%BTC$75,823.00-0.63%ETH$2,399.06-1.94%GOLD$4,386.20+1.23%OIL$103.57-2.14%
Smart Investors Daily
TP

NASDAQ · TPST

Tempest Therapeutics, Inc.

Healthcare · Biotechnology

$0.76

Up+$0.36 (+48.07%)

Updated Sep 16, 2026, 1:43 PM

SID Score

2.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
14.1M
P/E ratio
-0.28
Dividend yield
0.00%
52-week range
$0.74 – $6.12
Volume
26.44M
Avg. volume
107.23K

Price performance

TPST price history

1M range · 20 trading sessions · Daily adjusted prices

TPST closed at $0.76 after 20 trading sessions, down 29.40% for the selected period.

Last close
$0.76
Period change
-29.40%
Period low
$0.76
Period high
$1.11
Daily close
View OHLC price history
TPST OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$0.799$0.8094$0.7432$0.755426.44M
Sep 14, 2026$0.80$0.8221$0.7522$0.7843143.42K
Sep 11, 2026$0.79$0.8872$0.7583$0.8117783.63K
Sep 10, 2026$0.95$0.95$0.80$0.8026391.01K
Sep 9, 2026$0.985$0.99$0.9088$0.9089189.5K
Sep 8, 2026$1.02$1.03$0.976$0.9872199.94K
Sep 4, 2026$1.04$1.05$1.01$1.03214.71K
Sep 3, 2026$1.10$1.10$1.04$1.05182.26K
Sep 2, 2026$1.05$1.12$1.05$1.10127.7K
Sep 1, 2026$1.07$1.08$1.0311$1.05177.33K
Aug 31, 2026$1.06$1.13$1.06$1.0960.83K
Aug 28, 2026$1.0919$1.10$1.04$1.0664.07K
Aug 27, 2026$1.10$1.11$1.0749$1.0870.5K
Aug 26, 2026$1.1088$1.1095$1.07$1.0851.77K
Aug 25, 2026$1.11$1.13$1.08$1.1175.81K
Aug 24, 2026$1.05$1.14$1.01$1.10201.24K
Aug 21, 2026$1.02$1.08$1.00$1.04133.86K
Aug 20, 2026$1.05$1.0748$1.005$1.0289.58K
Aug 19, 2026$1.02$1.08$1.02$1.07155.96K
Aug 18, 2026$1.11$1.11$1.0101$1.07334.95K

Latest TPST news

The latest Smart Investors Daily articles mentioning TPST.

Stock researchCompany · Overview

TPST research

Overview

Company profile and research snapshot.

Company profile

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TPST recent ratings
DateFirmRatingTarget
Jan 22, 2026HC Wainwright & Co.Buy—
Apr 10, 2025ScotiabankSector Perform—
Apr 10, 2025HC Wainwright & Co.Neutral—
Mar 28, 2025ScotiabankSector Outperform—
Mar 28, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 11, 2026

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrantsBRISBANE, Calif. , Sept. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,105,591

Yahoo · Sep 8, 2026

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

BRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that Matt Angel, Ph.D., Tempest’s President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. ET. The webcast will be posted to Tempest’s w

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By